Effects of Dapagliflozin on 24-Hour Glycemic Control in Patients with Type 2 Diabetes: A Randomized Controlled Trial | Zendy

Robert R. Henry | Zendy; Poul Strange | Zendy; Rong Zhou | Zendy; Jeremy Pettus | Zendy; Leon Shi | Zendy; Sergey B. Zhuplatov | Zendy; Traci A. Mansfield | Zendy; David J. Klein | Zendy; Arie Katz | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Effects of Dapagliflozin on 24-Hour Glycemic Control in Patients with Type 2 Diabetes: A Randomized Controlled Trial

Author(s) -

Robert R. Henry,

Poul Strange,

Rong Zhou,

Jeremy Pettus,

Leon Shi,

Sergey B. Zhuplatov,

Traci A. Mansfield,

David J. Klein,

Arie Katz

Publication year - 2018

Publication title -

diabetes technology and therapeutics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.142

H-Index - 88

eISSN - 1557-8593

pISSN - 1520-9156

DOI - 10.1089/dia.2018.0052

Subject(s) - dapagliflozin , medicine , glycemic , placebo , metformin , postprandial , hypoglycemia , type 2 diabetes , diabetes mellitus , insulin , glycated hemoglobin , adverse effect , randomized controlled trial , urinary system , endocrinology , gastroenterology , urology , alternative medicine , pathology

Glycated hemoglobin (HbA1c) and measures of short-term glycemia do not fully capture daily patterns in plasma glucose dynamics. This study evaluated 24-h glycemic profiles in patients with type 2 diabetes (T2D) initiated on dapagliflozin treatment using continuous glucose monitoring (CGM).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research